Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions.
Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is eligible to receive up to $2.1 billion in upfront and milestone payments, along with tiered royalties tied to future net sales, according to a Feb. 25 news release.
The collaboration aims to enable oral delivery of peptide and protein therapeutics that are typically limited to injections because of low gastrointestinal absorption. Vivtex’s platform combines high-throughput gastrointestinal screening, drug delivery technologies and AI-driven analytics designed to improve oral bioavailability and performance.
Novo Nordisk will lead global development, regulatory activities, manufacturing and commercialization of any resulting products.
The post Novo Nordisk inks $2.1B oral obesity drug deal appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
